Evaluation of Human Leukocyte Antigen Class I and Class II in End-Stage Renal Disease Occurrence in Indonesian Transplantation Patients

Table 2

HLA class II allele frequency.

HLA subtype	Alleles	ESRD		Control		OR	OR 95% CI	value
		n	%	n	%
HLA-DRB1	DRB103	5	3.60	2	1.30	2.97	0.567–15.56	0.34
	DRB104	6	4.30	7	4.40	0.994	0.326–3.03	1
	DRB107	9	6.50	14	8.80	0.728	0.305–1.74	0.62
	DRB108	7	5.10	4	2.50	2.084	0.597–7.28	0.39
	DRB109	4	2.90	3	1.90	1.562	0.344–7.10	0.84
	DRB110	3	2.20	0	0	—	—	—
	DRB111	3	2.20	4	2.50	0.867	0.191–3.94	1
	DRB112	61	44.20	80	50	0.792	0.502–1.25	0.38
	DRB114	5	3.60	3	1.90	1.967	0.462–8.39	0.57
	DRB115	31	22.50	38	23.80	0.93	0.542–1.60	0.90
	DRB116	2	1.40	4	2.50	0.574	0.103–3.18	0.83
HLA-DQB1	DQB102	11	8	17	10.70	0.729	0.329–1.61	0.56
	DQB103	68	49.30	83	51.90	0.901	0.572–1.42	0.74
	DQB104	5	3.60	6	3.70	0.965	0.288–3.23	1
	DQB105	33	23.90	31	19.30	1.308	0.752–2.28	0.42
	DQB106	21	15.20	23	14.40	1.069	0.563–2.03	0.97
HLA-DPB1	DPB101	5	3.60	6	3.80	0.965	0.288–3.23	1.00
	DPB102	20	14.50	13	8.10	1.917	0.915–4.01	0.12
	DPB103	8	5.80	15	9.40	0.595	0.244–1.45	0.35
	DPB104	29	21	34	21.30	0.986	0.564–1.72	1.00
	DPB105	24	17.40	26	16.30	1.085	0.591–1.99	0.91
	DPB113	31	22.50	36	22.50	0.998	0.578–1.72	1.00
	DPB114	0	0	4	2.50	—	—	—
	DPB119	1	0.70	2	1.30	0.577	0.052–6.43	1
	DPB126	0	0	2	1.30	—	—	—
	DPB131	0	0	2	1.30	—	—	—
	DPB1105	4	2.90	2	1.30	2.358	0.425–13.08	0.55
	DPB1296	7	5.10	10	6.30	0.802	0.297–2.17	0.86
	DPB1350	3	2.20	2	1.30	1.756	0.289–10.66	0.86

HLA types with frequency >1% were performed in ESRD or control groups. HLA: human leukocyte antigen; ESRD: end-stage renal disease.